Sorafenib

mitogen-activated protein kinase 1 ; Mus musculus







21 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34339801 Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance. 2021 Nov 1 2
2 34445279 Secretory NPC2 Protein-Mediated Free Cholesterol Levels Were Correlated with the Sorafenib Response in Hepatocellular Carcinoma. 2021 Aug 9 1
3 32434082 Hybrid membrane camouflaged copper sulfide nanoparticles for photothermal-chemotherapy of hepatocellular carcinoma. 2020 Jul 15 1
4 33021963 MicroRNA-216a-3p promotes sorafenib sensitivity in hepatocellular carcinoma by downregulating MAPK14 expression. 2020 Sep 21 1
5 28053052 ERK activation and autophagy impairment are central mediators of irinotecan-induced steatohepatitis. 2018 Apr 1
6 29196297 Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers. 2018 Mar 1 1
7 29463989 Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. 2018 4
8 29599330 Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma In Vivo. 2018 Apr 1
9 30126548 Lymphocyte-Specific Protein-1 Controls Sorafenib Sensitivity and Hepatocellular Proliferation through Extracellular Signal-Regulated KinaseĀ 1/2 Activation. 2018 Sep 2
10 28282575 Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo. 2017 May 3
11 28661484 Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury. 2017 Jun 29 1
12 25418579 Generation of a murine hepatic angiosarcoma cell line and reproducible mouse tumor model. 2015 Mar 1
13 26287667 TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression. 2015 Sep 29 1
14 25436606 Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3. 2014 1
15 22653837 Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. 2012 Dec 2
16 22753710 The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment. 2012 Jul 3
17 20015197 Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. 2011 Feb 1
18 21693435 cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma. 2011 Aug 1
19 19276184 Tie2 in tumor endothelial signaling and survival: implications for antiangiogenic therapy. 2009 Mar 2
20 19432991 Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotion. 2009 May 11 2
21 19723882 AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer. 2009 Sep 4